16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Beta Amyloid Deposition Is Not Associated With Cognitive Impairment in Parkinson's Disease

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is unresolved. Here, we used Florbetaben PET imaging to test for any association between cerebral amyloid deposition and cognitive impairment in PD, in a sample enriched for cases with mild cognitive impairment. This cross-sectional study used Movement Disorders Society level II criteria to classify 115 participants with PD as having normal cognition (PDN, n = 23), mild cognitive impairment (PD-MCI, n = 76), or dementia (PDD, n = 16). We acquired 18F-Florbetaben (FBB) amyloid PET and structural MRI. Amyloid deposition was assessed between the three cognitive groups, and also across the whole sample using continuous measures of both global cognitive status and average performance in memory domain tests. Outcomes were cortical FBB uptake, expressed in centiloids and as standardized uptake value ratios (SUVR) using the Centiloid Project whole cerebellum region as a reference, and regional SUVR measurements. FBB binding was higher in PDD, but this difference did not survive adjustment for the older age of the PDD group. We established a suitable centiloid cut-off for amyloid positivity in Parkinson's disease (31.3), but there was no association of FBB binding with global cognitive or memory scores. The failure to find an association between PET amyloid deposition and cognitive impairment in a moderately large sample, particularly given that it was enriched with PD-MCI patients at risk of dementia, suggests that amyloid pathology is not the primary driver of cognitive impairment and dementia in most patients with PD.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          Decreased volume of left and total anterior insular lobule in schizophrenia.

          The insula is anatomically situated to be critically involved in many bio-behavioral functions impaired in schizophrenia. Furthermore, its total volume has been shown to be reduced in schizophrenia. In the present study, we tested the hypothesis that in schizophrenia it is the anterior insular lobule (aINS(lbl)) rather than the posterior insular lobule (pINS(lbl)) that is smaller, given that limbic system abnormalities are central in schizophrenia and that the affiliations of the limbic system are principally with the anterior insular lobule. We used T1-weighted high resolution magnetic resonance imaging (MRI) to measure the cortical volume of the left and right anterior and posterior insular subdivisions. The subjects included a sample of healthy community controls (N=40) and chronic patients with DSM-III-R schizophrenia (N=41). We correlated insula volumes with positive and negative symptoms. We found that the total aINS(lbl), and the left aINS(lbl) in particular, were significantly volumetrically smaller in schizophrenia compared to controls, and significantly correlated with bizarre behavior. Given that the anterior insular lobule offers anatomic features that allow for MRI-based morphometric analysis, namely its central and circular sulci, this brain structure provides a useful model to test hypotheses regarding genotype-phenotype relationships in schizophrenia using the anterior insular lobule as a candidate endophenotype.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Structural brain magnetic resonance imaging of limbic and thalamic volumes in pediatric bipolar disorder.

            Youths with bipolar disorder are ideal for studying illness pathophysiology given their early presentation, lack of extended treatment, and high genetic loading. Adult bipolar disorder MRI studies have focused increasingly on limbic structures and the thalamus because of their role in mood and cognition. On the basis of adult studies, the authors hypothesized a priori that youths with bipolar disorder would have amygdalar, hippocampal, and thalamic volume abnormalities. Forty-three youths 6-16 years of age with DSM-IV bipolar disorder (23 male, 20 female) and 20 healthy comparison subjects (12 male, eight female) similar in age and sex underwent structured and clinical interviews, neurological examination, and cognitive testing. Differences in limbic and thalamic brain volumes, on the logarithmic scale, were tested using a two-way (diagnosis and sex) univariate analysis of variance, with total cerebral volume and age controlled. The subjects with bipolar disorder had smaller hippocampal volumes. Further analysis revealed that this effect was driven predominantly by the female bipolar disorder subjects. In addition, both male and female youths with bipolar disorder had significantly smaller cerebral volumes. No significant hemispheric effects were seen. These findings support the hypothesis that the limbic system, in particular the hippocampus, may be involved in the pathophysiology of pediatric bipolar disorder. While this report may represent the largest MRI study of pediatric bipolar disorder to date, more work is needed to confirm these findings and to determine if they are unique to pediatric bipolar disorder.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?

              The relative importance of Lewy- and Alzheimer-type pathologies to dementia in Parkinson's disease remains unclear. We have examined the combined associations of α-synuclein, tau and amyloid-β accumulation in 56 pathologically confirmed Parkinson's disease cases, 29 of whom had developed dementia. Cortical and subcortical amyloid-β scores were obtained, while tau and α-synuclein pathologies were rated according to the respective Braak stages. Additionally, cortical Lewy body and Lewy neurite scores were determined and Lewy body densities were generated using morphometry. Non-parametric statistics, together with regression models, receiver-operating characteristic curves and survival analyses were applied. Cortical and striatal amyloid-β scores, Braak tau stages, cortical Lewy body, Lewy neurite scores and Lewy body densities, but not Braak α-synuclein stages, were all significantly greater in the Parkinson's disease-dementia group (P<0.05), with all the pathologies showing a significant positive correlation to each other (P<0.05). A combination of pathologies [area under the receiver-operating characteristic curve=0.95 (0.88-1.00); P<0.0001] was a better predictor of dementia than the severity of any single pathology. Additionally, cortical amyloid-β scores (r=-0.62; P=0.043) and Braak tau stages (r=-0.52; P=0.028), but not Lewy body scores (r=-0.25; P=0.41) or Braak α-synuclein stages (r=-0.44; P=0.13), significantly correlated with mini-mental state examination scores in the subset of cases with this information available within the last year of life (n=15). High cortical amyloid-β score (P=0.017) along with an older age at onset (P=0.001) were associated with a shorter time-to-dementia period. A combination of Lewy- and Alzheimer-type pathologies is a robust pathological correlate of dementia in Parkinson's disease, with quantitative and semi-quantitative assessment of Lewy pathology being more informative than Braak α-synuclein stages. Cortical amyloid-β and age at disease onset seem to determine the rate to dementia.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Neurol
                Front Neurol
                Front. Neurol.
                Frontiers in Neurology
                Frontiers Media S.A.
                1664-2295
                24 April 2019
                2019
                : 10
                : 391
                Affiliations
                [1] 1New Zealand Brain Research Institute , Christchurch, New Zealand
                [2] 2Department of Medicine, University of Otago , Christchurch, New Zealand
                [3] 3Brain Research New Zealand Rangahau Roro Aotearoa Centre of Research Excellence , Christchurch, New Zealand
                [4] 4Pacific Radiology Group , Christchurch, New Zealand
                [5] 5Department of Neurology, Huashan Hospital, Fudan University , Shanghai, China
                [6] 6Department of Physics and Astronomy, University of Canterbury , Christchurch, New Zealand
                [7] 7Institute of Neurology, University College London , London, United Kingdom
                [8] 8Department of Psychology, University of Canterbury , Christchurch, New Zealand
                [9] 9Department of Neurology, Christchurch Hospital , Christchurch, New Zealand
                Author notes

                Edited by: Salvatore Galati, Neurocenter of Southern Switzerland (NSI), Switzerland

                Reviewed by: Matthias Brendel, Ludwig Maximilian University of Munich, Germany; Paul Cumming, University of Bern, Switzerland

                *Correspondence: Tim J. Anderson tim.anderson@ 123456cdhb.health.nz

                This article was submitted to Movement Disorders, a section of the journal Frontiers in Neurology

                †These authors have contributed equally to this work and are co-first authors

                Article
                10.3389/fneur.2019.00391
                6492461
                31105633
                ee59cd08-61a1-403e-a8a9-56eab54583b4
                Copyright © 2019 Melzer, Stark, Keenan, Myall, MacAskill, Pitcher, Livingston, Grenfell, Horne, Young, Pascoe, Almuqbel, Wang, Marsh, Miller, Dalrymple-Alford and Anderson.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 11 February 2019
                : 01 April 2019
                Page count
                Figures: 4, Tables: 1, Equations: 0, References: 66, Pages: 9, Words: 7211
                Funding
                Funded by: Health Research Council of New Zealand 10.13039/501100001505
                Funded by: Neurological Foundation of New Zealand 10.13039/501100001543
                Funded by: Canterbury Medical Research Foundation 10.13039/501100001530
                Categories
                Neurology
                Original Research

                Neurology
                parkinson's disease,amyloid pet,florbetaben,dementia,centiloid,mild cognitive impairment
                Neurology
                parkinson's disease, amyloid pet, florbetaben, dementia, centiloid, mild cognitive impairment

                Comments

                Comment on this article